Lilly Focuses Xigris Promotion On Physician “Peer-To-Peer” Discussions
Executive Summary
Lilly believes "peer-to-peer" discussions about positive experiences with Xigris will energize sales of the sepsis agent, Exec VP-Pharmaceutical Products & Corporate Development John Lechleiter, PhD, said
You may also be interested in...
Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages
Lilly is planning to publish a series of peer-reviewed Xigris journal articles as part of a continued effort to build market acceptance of the sepsis agent
Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages
Lilly is planning to publish a series of peer-reviewed Xigris journal articles as part of a continued effort to build market acceptance of the sepsis agent
Lilly Foresees No Zyprexa Diabetes Warning In U.S.; Pfizer Sees Opening
Lilly does not anticipate a diabetes contraindication in U.S. labeling for Zyprexa (olanzapine) in the wake of a likely relabeling in Japan